Serum pepsinogen II is a better diagnostic marker in gastric cancer

15/03/2016
Author:  Xue-Yaun Cao et al - World J Gastroenterology 2012 - December 28; 18(48): 7357 – 7361

Xue-Yaun Cao et al,
World J Gastroenterology 2012, December 28; 18(48): 7357 – 7361

Abstract

Aim:
To investigate screening makers for gastric cancer, we assessed the association between gastric cancer and serum pepsinogens (PGs).

Methods:
The subjects comprised 450 patients with gastric cancer, 111 individuals with gastric atrophy, and 961 healthy controls. Serum anti-Helicobacter pylori (H. pylori) immunoglobulin G (IgG), PGⅠand PG Ⅱ were detected by enzyme-linked immunosorbent assay.  Gastric atrophy and gastric cancer were diagnosed by endoscopy and histopathological examinations. Odds ratios and 95%CIs were calculated using multivariate logistic regression.

Results:
Rates of H. pylori infection remained high in Northeastern China. Rates of H. pylori IgG positivity were greater in the gastric cancer and gastric atrophy groups compared to the control group (69.1% and 75.7% vs 49.7%, P < 0.001). Higher levels of PG Ⅱ (15.9 μg/L and 13.9 μg/L vs 11.5 μg/L, P < 0.001) and lower PGⅠ/ PG Ⅱ ratio (5.4 and 4.6 vs 8.4, P < 0.001) were found in patients with gastric cancer or gastric atrophy compared to healthy controls, whereas no correlation was found between the plasma PGⅠconcentration and risk of gastric cancer (P = 0.537). In addition, multivariate logistic analysis indicated that H. pylori infection and atrophic gastritis were independent risk factors for gastric cancer. Lower plasma PGⅠ/PG Ⅱ ratio was associated with higher risks of atrophy and gastric cancer. Furthermore, plasma PG Ⅱ level significantly correlated with H. pylori - infected gastric cancer.

Conclusion:

Serum PG Ⅱ concentration and PG Ⅰ/PG Ⅱ ratio are potential biomarkers for H. pylori-infected gastric disease. PG Ⅱ is independently associated with risk of gastric cancer.

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.